The CDC estimates that there were more than 26 million new cases of STIs in the United States in 2018 alone. Source
UTI (STI) Panel
Urinary tract infections (UTIs) are the most common outpatient infections, with a lifetime incidence of 50−60% in adult women. Source
Studies have shown that up to 67% of uropathogens may be missed with standard urine culture. Source
PCR & Antibiotic Susceptibility Test (AST)
Run both, together.
The New Gold Standard
Our all-in-one UTI/STI panel provides physicians with the ability to detect a broad spectrum of urinary tract pathogens and the presence of corresponding antibiotic resistance markers. This enables clinicians to prescribe the most effective treatments for their patients.
Additionally, the use of molecular diagnostic testing for UTIs and STIs eliminates the possibility of “no-growth” results and can identify pathogens that are difficult to detect in traditional urine cultures.
For our UTI/STI panel, we have partnered with Coriell reporting to provide clinicians with suggested treatment options based on the detection of antibiotic resistance markers.